| Literature DB >> 24895604 |
Alexey V Polonikov1, Vladimir P Ivanov1, Alexey D Bogomazov2, Maxim B Freidin3, Thomas Illig4, Maria A Solodilova1.
Abstract
Oxidative stress resulting from an increased amount of reactive oxygen species and an imbalance between oxidants and antioxidants plays an important role in the pathogenesis of asthma. The present study tested the hypothesis that genetic susceptibility to allergic and nonallergic variants of asthma is determined by complex interactions between genes encoding antioxidant defense enzymes (ADE). We carried out a comprehensive analysis of the associations between adult asthma and 46 single nucleotide polymorphisms of 34 ADE genes and 12 other candidate genes of asthma in Russian population using set association analysis and multifactor dimensionality reduction approaches. We found for the first time epistatic interactions between ADE genes underlying asthma susceptibility and the genetic heterogeneity between allergic and nonallergic variants of the disease. We identified GSR (glutathione reductase) and PON2 (paraoxonase 2) as novel candidate genes for asthma susceptibility. We observed gender-specific effects of ADE genes on the risk of asthma. The results of the study demonstrate complexity and diversity of interactions between genes involved in oxidative stress underlying susceptibility to allergic and nonallergic asthma.Entities:
Mesh:
Substances:
Year: 2014 PMID: 24895604 PMCID: PMC4026955 DOI: 10.1155/2014/708903
Source DB: PubMed Journal: Biomed Res Int Impact factor: 3.411
Description of the polymorphisms included in this study.
|
Gene symbols | Gene name | Polymorphism (SNP) | Location | SNP ID | |
|---|---|---|---|---|---|
| 1 | 2 | 3 | 4 | 5 | 6 |
|
| |||||
| 1 |
| Glutathione peroxidase 1 | C>T (P198L) | exon 1 | rs1050450 |
| 2 |
| Glutathione peroxidase 2 (gastrointestinal) | G>A (R146C) | exon 2 | rs17880492 |
| 3 |
| Glutathione peroxidase 3 (plasma) | 249G>A | 3′ UTR | rs2070593 |
| 4 |
| Glutathione peroxidase 4 (phospholipid hydroperoxidase) | C718T | 3′ UTR | rs713041 |
| 5 |
| Glutathione reductase | T>C (30546636T>C) | intron 9 | rs2551715 |
| 6 |
| Superoxide dismutase 2, mitochondrial | A16V | exon 2 | rs4880 |
| 7 |
| Superoxide dismutase 3, extracellular | A40T (A58T) | exon 3 | rs2536512 |
| 8 |
| Catalase | −21A>T (−89A>T) | 5′ UTR | rs7943316 |
| 9 |
| −262C>T (4760C>T) | 5′ UTR | rs1001179 | |
| 10 |
| Glutamate-cysteine ligase, modifier subunit | −588C>T (4704C>T) | 5′ UTR | rs41303970 |
| 11 |
| −23G>T | 5′UTR | rs743119 | |
| 12 |
| NAD(P)H dehydrogenase, quinone 1 | P187S | exon 6 | rs1800566 |
| 13 |
| R139W | exon 4 | rs4986998 | |
| 14 |
| Cytochrome b-245, alpha polypeptide | 242C>T (Y72H) | exon 4 | rs4673 |
| 15 |
| 640A>G (24G>A) | 3′ UTR | rs1049255 | |
| 16 |
| −930A>G | 5′ UTR | rs9932581 | |
| 17 |
| Myeloperoxidase | −463G>A (4535G>A) | 5′ UTR | rs2333227 |
| 18 |
| Peroxiredoxin 1 | C>A | 5′ UTR | rs17522918 |
| 19 |
| Thioredoxin reductase 1 | C>G | 5′ UTR | rs1128446 |
| 20 |
| Flavin-containing monooxygenase 3 | E158K | exon 4 | rs2266782 |
| 21 |
| Cytochrome P450, family 1, subfamily A, polypeptide 1 | I462V | exon 7 | rs1048943 |
| 22 |
| T6235C | 3′ UTR | rs4646903 | |
| 23 |
| Cytochrome P450, family 2, subfamily | −1293G>C | 5′ UTR | rs3813867 |
| 24 |
| −1053C>T | 5′ UTR | rs2031920 | |
| 25 |
| 7632T>A | intron 6 | rs6413432 | |
| 26 |
| 9896C>G | intron 7 | rs2070676 | |
| 27 |
| Epoxide hydrolase 1, microsomal (xenobiotic) | Y113H (337T>C) | exon 3 | rs1051740 |
| 28 |
| H139R (416A>G) | exon 4 | rs2234922 | |
| 29 |
| Paraoxonase 1 | Q192R | exon 6 | rs662 |
| 30 |
| Paraoxonase 2 | C311S | exon 9 | rs7493 |
| 31 |
| Glutathione S-transferase mu 1 | Expressor/deletion | exons 6-7 | — |
| 32 |
| Glutathione S-transferase theta 1 | Expressor/deletion | exon 4 | — |
| 33 |
| Glutathione S-transferase pi 1 | I105V | exon 5 | rs1695 |
| 34 |
| A114V | exon 6 | rs1138272 | |
| 35 |
| Tumor necrosis factor | −308G>A | 5′ UTR | rs1800629 |
| 36 |
| Interleukin 1, beta | −511C>T | 5′ UTR | rs16944 |
| 37 |
| Interleukin 3 (colony-stimulating factor, multiple) | S27P | exon 1 | rs40401 |
| 38 |
| −15C>T | 5′ UTR | rs31480 | |
| 39 |
| Interleukin 5 (colony-stimulating factor, eosinophil) | C-703T | 5′ UTR | rs2069812 |
| 40 |
| Colony stimulating factor 2 receptor, beta, low-affinity (granulocyte-macrophage) | G1972A | exon 5 | rs131840 |
| 41 |
| Interleukin 9 | T113M | exon 5 | rs2069885 |
| 42 |
| Interleukin 13 | −1111C>T | 5′ UTR | rs1800925 |
| 43 |
| Secretoglobin, family 1A, member 1 (uteroglobin) | A38G | exon 1 | rs11549442 |
| 44 |
| Serpin peptidase inhibitor, clade A (alpha-1 antiproteinase, antitrypsin), member 1 | E288V | exon 3 | rs17580 |
| 45 |
| D365N | exon 5 | rs143370956 | |
| 46 |
| 1331G>A | 3′ UTR | rs11568814 | |
Allele frequencies of genes investigated in the present study.
| Gene | Polymorphism | Alleles | Allele frequency | |||
|---|---|---|---|---|---|---|
| Controls ( | Asthma, entire group | Allergic asthma ( | Nonallergic asthma ( | |||
| 1 | 2 | 3 | 4 | 5 | 6 | 7 |
|
| ||||||
|
| G>A | G | 0.991 | 0.981 | 0.987 | 0.964 |
| A | 0.009 | 0.019 | 0.013 | 0.036 | ||
|
| G>A | G | 0.703 | 0.726 | 0.734 | 0.696 |
| A | 0.297 | 0.274 | 0.266 | 0.304 | ||
|
| C718T | 718T | 0.402 | 0.391 | 0.407 | 0.348 |
| 718C | 0.598 | 0.609 | 0.593 | 0.652 | ||
|
| T>C | T | 0.442 | 0.398 | 0.362 | 0.491 |
| C | 0.558 | 0.602 | 0.638* | 0.509 | ||
|
| A16V | 16A | 0.528 | 0.486 | 0.481 | 0.509 |
| 16V | 0.472 | 0.514 | 0.519 | 0.491 | ||
|
| A40T | 40A | 0.322 | 0.321 | 0.324 | 0.295 |
| 40T | 0.678 | 0.679 | 0.676 | 0.705 | ||
|
| C>A | C | 0.923 | 0.937 | 0.942 | 0.920 |
| A | 0.077 | 0.063 | 0.058 | 0.080 | ||
|
| C>G | C | 0.808 | 0.821 | 0.808 | 0.857 |
| G | 0.192 | 0.179 | 0.192 | 0.143 | ||
|
| E158K | 158E | 0.549 | 0.537 | 0.529 | 0.571 |
| 158K | 0.451 | 0.463 | 0.471 | 0.429 | ||
|
| −308G>A | −308G | 0.888 | 0.872 | 0.875 | 0.866 |
| −308A | 0.112 | 0.128 | 0.125 | 0.134 | ||
|
| −511C>T | −511C | 0.710 | 0.664 | 0.670 | 0.652 |
| −511T | 0.290 | 0.336 | 0.330 | 0.348 | ||
|
| S27P | 27S | 0.738 | 0.685 | 0.686 | 0.688 |
| 27P | 0.262 | 0.315 | 0.314 | 0.313 | ||
|
| −15C>T | −15C | 0.741 | 0.683 | 0.686 | 0.688 |
| −15T | 0.259 | 0.317 | 0.314 | 0.313 | ||
|
| C-703T | −703C | 0.673 | 0.778 | 0.788 | 0.732 |
| −703T | 0.327 | 0.222* | 0.212* | 0.268 | ||
|
| G1972A | 1972G | 0.831 | 0.866 | 0.872 | 0.848 |
| 1972A | 0.169 | 0.134 | 0.128 | 0.152 | ||
|
| T113M | 113T | 0.820 | 0.863 | 0.856 | 0.893 |
| 113M | 0.180 | 0.137 | 0.144 | 0.107 | ||
|
| −1111C>T | −1111C | 0.729 | 0.693 | 0.692 | 0.714 |
| −1111T | 0.271 | 0.307 | 0.308 | 0.286 | ||
|
| A38G | 38A | 0.347 | 0.367 | 0.372 | 0.366 |
| 38G | 0.653 | 0.633 | 0.628 | 0.634 | ||
|
| E288V | 288E | 0.993 | 0.991 | 0.990 | 0.991 |
| 288V | 0.007 | 0.009 | 0.010 | 0.009 | ||
|
| D365N | 365D | 0.991 | 0.995 | 0.997 | 0.991 |
| 365N | 0.009 | 0.005 | 0.003 | 0.009 | ||
|
| 1331G>A | 1331G | 0.937 | 0.933 | 0.926 | 0.946 |
| 1331A | 0.063 | 0.067 | 0.074 | 0.054 | ||
*Indicates a difference in minor allele frequency between asthmatics and controls.
Genotype frequencies of genes investigated in the present study.
| Gene | Polymorphism | Genotypes | Genotype distributions, | |||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Controls ( | Asthma, entire group ( | Allergic asthma ( | Nonallergic asthma ( | |||||||
| 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 |
|
| ||||||||||
|
| G>A | GG | 210 | 98.1 | 207 | 96.3 | 152 | 97.4 | 52 | 92.9 |
| GA | 4 | 1.9 | 8 | 3.7 | 4 | 2.6 | 4 | 7.1 | ||
| AA | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | ||
|
| G>A | GG | 105 | 49.1 | 113 | 52.6 | 83 | 53.2 | 28 | 50.0 |
| GA | 91 | 42.5 | 86 | 40.0 | 63 | 40.4 | 22 | 39.3 | ||
| AA | 18 | 8.4 | 16 | 7.4 | 10 | 6.4 | 6 | 10.7 | ||
|
| C718T | 718TT | 31 | 14.5 | 33 | 15.3 | 25 | 16.0 | 8 | 14.3 |
| 718TC | 110 | 51.4 | 102 | 47.4 | 77 | 49.4 | 23 | 41.1 | ||
| 718CC | 73 | 34.1 | 80 | 37.2 | 54 | 34.6 | 25 | 44.6 | ||
|
| T>C | TT | 40 | 18.7 | 32 | 14.9 | 17 | 10.9* | 15 | 26.8 |
| TC | 109 | 50.9 | 107 | 49.8 | 79 | 50.6 | 25 | 44.6 | ||
| CC | 65 | 30.4 | 76 | 35.3 | 60 | 38.5 | 16 | 28.6 | ||
|
| A16V | 16AA | 59 | 27.6 | 49 | 22.8 | 34 | 21.8 | 15 | 26.8 |
| 16AV | 108 | 50.5 | 111 | 51.6 | 82 | 52.6 | 27 | 48.2 | ||
| 16VV | 47 | 22.0 | 55 | 25.6 | 40 | 25.6 | 14 | 25.0 | ||
|
| A40T | 40AA | 21 | 9.8 | 24 | 11.2 | 19 | 12.2 | 4 | 7.1 |
| 40AT | 96 | 44.9 | 90 | 41.9 | 63 | 40.4 | 25 | 44.6 | ||
| 40TT | 97 | 45.3 | 101 | 47.0 | 74 | 47.4 | 27 | 48.2 | ||
|
| C>A | CC | 182 | 85.0 | 188 | 87.4 | 138 | 88.5 | 47 | 83.9 |
| CA | 31 | 14.5 | 27 | 12.6 | 18 | 11.5 | 9 | 16.1 | ||
| AA | 1 | 0.5 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | ||
|
| C>G | CC | 140 | 65.4 | 145 | 67.4 | 101 | 64.7 | 42 | 75.0 |
| CG | 66 | 30.8 | 63 | 29.3 | 50 | 32.1 | 12 | 21.4 | ||
| GG | 8 | 3.7 | 7 | 3.3 | 5 | 3.2 | 2 | 3.6 | ||
|
| E158K | 158EE | 57 | 26.6 | 59 | 27.4 | 39 | 25.0 | 20 | 35.7 |
| 158EK | 121 | 56.5 | 113 | 52.6 | 87 | 55.8 | 24 | 42.9 | ||
| 158KK | 36 | 16.8 | 43 | 20.0 | 30 | 19.2 | 12 | 21.4 | ||
|
| −308G>A | −308GG | 170 | 79.4 | 162 | 75.4 | 118 | 75.6 | 42 | 75.0 |
| −308GA | 40 | 18.7 | 51 | 23.7 | 37 | 23.7 | 13 | 23.2 | ||
| −308AA | 4 | 1.9 | 2 | 0.9 | 1 | 0.6 | 1 | 1.8 | ||
|
| −511C>T | −511CC | 114 | 53.3 | 91 | 42.1 | 67 | 43.0* | 23 | 41.1 |
| −511CT | 76 | 35.5 | 105 | 48.6 | 75 | 48.1* | 27 | 48.2 | ||
| −511TT | 24 | 11.2 | 20 | 9.3 | 14 | 9.0 | 6 | 10.7 | ||
|
| S27P | 27SS | 120 | 56.1 | 104 | 48.2 | 77 | 49.4 | 25 | 44.6 |
| 27SP | 76 | 35.5 | 88 | 40.7 | 60 | 38.5 | 27 | 48.2 | ||
| 273P | 18 | 8.4 | 24 | 11.1 | 19 | 12.2 | 4 | 7.1 | ||
|
| −15C>T | −15CC | 120 | 56.1 | 103 | 47.7 | 77 | 49.4 | 25 | 44.6 |
| −15CT | 77 | 36.0 | 89 | 41.2 | 60 | 38.5 | 27 | 48.2 | ||
| −15TT | 17 | 7.9 | 24 | 11.1 | 19 | 12.2 | 4 | 7.1 | ||
|
| C-703T | −703CC | 90 | 42.1 | 132 | 61.1 | 97 | 62.2* | 31 | 55.4 |
| −703CT | 108 | 50.5 | 72 | 33.3 | 52 | 33.3* | 20 | 35.7* | ||
| −703TT | 16 | 7.5 | 12 | 5.6 | 7 | 4.5 | 5 | 8.9 | ||
|
| G1972A | 1972GG | 136 | 67.7 | 160 | 74.1 | 118 | 75.6 | 39 | 69.6 |
| 1972GA | 62 | 30.9 | 54 | 25.0 | 36 | 23.1 | 17 | 30.4 | ||
| 1972AA | 3 | 1.5 | 2 | 0.9 | 2 | 1.3 | 0 | 0.0 | ||
|
| T113M | 113TT | 146 | 68.2 | 159 | 73.6 | 113 | 72.4 | 44 | 78.6 |
| 113TM | 59 | 27.6 | 55 | 25.5 | 41 | 26.3 | 12 | 21.4 | ||
| 113MM | 9 | 4.2 | 2 | 0.9 | 2 | 1.3 | 0 | 0.0 | ||
|
| −1111C>T | −1111CC | 114 | 53.3 | 101 | 47.0 | 75 | 48.1 | 26 | 46.4 |
| −1111CT | 84 | 39.3 | 96 | 44.7 | 66 | 42.3 | 28 | 50.0 | ||
| −1111CT | 16 | 7.5 | 18 | 8.4 | 15 | 9.6 | 2 | 3.6 | ||
|
| A38G | 38AA | 25 | 11.8 | 28 | 13.0 | 23 | 14.7 | 5 | 8.9 |
| 38AG | 97 | 45.8 | 102 | 47.4 | 70 | 44.9 | 31 | 55.4 | ||
| 38GG | 90 | 42.5 | 85 | 39.5 | 63 | 40.4 | 20 | 35.7 | ||
|
| E288V | 288EE | 211 | 98.6 | 212 | 98.1 | 153 | 98.1 | 55 | 98.2 |
| 288EV | 3 | 1.4 | 4 | 1.9 | 3 | 1.9 | 1 | 1.8 | ||
| 288VV | — | — | — | — | — | — | — | — | ||
|
| D365N | 365DD | 210 | 98.1 | 214 | 99.1 | 153 | 98.1 | 55 | 98.2 |
| 365DN | 4 | 1.9 | 2 | 0.9 | 3 | 1.9 | 1 | 1.8 | ||
| 365NN | — | — | — | — | — | — | — | — | ||
|
| 1331G>A | 1331GG | 188 | 87.9 | 187 | 86.6 | 133 | 85.3 | 50 | 89.3 |
| 1331GA | 25 | 11.7 | 29 | 13.4 | 23 | 14.7 | 6 | 10.7 | ||
| 1331AA | 1 | 0.5 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | ||
*Indicates a difference in genotype frequency between asthmatics and controls.
Figure 1The results of statistical modeling of gene-gene interactions in allergic asthma using set association approach. Significance level of S statistic as a function of the number n of SNPs in different genes which are included at each step for gene-gene interactions analysis. The smallest significance level, P min, occurs with 5 SNPs in males and with 3 SNPs in females. The interacting genes in the models are circled in red.
Figure 2The results of statistical modeling of gene-gene interactions in nonallergic asthma using set association approach. Significance level of S statistic as a function of the number n of SNPs in different genes which are included at each step for gene-gene interactions analysis. The smallest significance level, P min, occurs with 5 SNPs in males and with 2 SNPs in females. The interacting genes in the models are circled in red.
A summary of best 2-, 3-, and 4-locus models of gene-gene interactions obtained by MDR analysis in allergic and nonallergic asthma (exhaustive search algorithm).
| Number of loci | Best | Cross-validation consistency, % | Prediction error, % |
|---|---|---|---|
| Allergic asthma (men) | |||
| 2 |
| 40 | 52.5 |
| 3 |
| 50 | 50.3 |
| 4 |
| 30 | 53.6 |
|
| |||
| Allergic asthma (women) | |||
| 2 |
| 50 | 45.8 |
| 3 |
| 50 | 40.9 |
| 4 |
| 20 | 50.1 |
|
| |||
| Nonallergic asthma (men) | |||
| 2 |
| 30 | 52.3 |
| 3 |
| 20 | 57.0 |
| 4 |
| 30 | 49.2 |
|
| |||
| Nonallergic asthma (women) | |||
| 2 |
| 30 | 46.7 |
| 3 |
| 60 | 45.5 |
| 4 |
| 90 | 27.4 |
*Indicates best n-locus model of gene-gene interactions evaluated through 1000 permutation tests.
**A statistically significant (P value 0.001) model of gene-gene interactions.
Figure 3Dendrograms of gene-gene interactions in the pathogenetic variants of asthma (MDR method). Dendrograms show both complexity and diversity of interactions between polymorphic genes of antioxidant defense enzymes in allergic and nonallergic asthma (dendrograms are stratified by gender). Each dendrogram comprises a spectrum of lines representing a continuum from synergy (black) to redundancy (gray) of gene-gene interactions. The lines range from bold black, representing a high degree of synergy (positive information gain), thin black, representing a lesser degree, and dotted line representing the midway point between synergy and redundancy. On the redundancy end of the spectrum, the highest degree is represented by bold gray (negative information gain) with a lesser degree represented by thin gray.
Associations of genotype combinations with risk of allergic asthma (stratified by gender).
| Combinations of genotypes | Allergic asthma | Controls | Chi-square | OR (95% CI) | ||
|---|---|---|---|---|---|---|
|
| % |
| % | |||
| Men | ||||||
|
| 34 | 53.1 | 38 | 36.2 | 4.66 (0.03) | 2.00 (1.06–3.76) |
|
| 20 | 31.3 | 19 | 18.1 | 3.88 (0.05) | 2.06 (1.00–4.25) |
|
| 7 | 10.9 | 2 | 1.9 | 4.77 (0.03) | 5.40 (1.25–23.42) |
|
| 12 | 18.8 | 6 | 5.7 | 5.80 (0.02) | 3.64 (1.33–9.96) |
|
| 18 | 28.1 | 13 | 12.4 | 6.58 (0.01) | 2.77 (1.25–6.14) |
|
| 12 | 18.8 | 7 | 6.7 | 4.67 (0.03) | 3.13 (1.19–8.21) |
|
| 38 | 59.4 | 44 | 41.9 | 4.86 (0.03) | 2.03 (1.08–3.81) |
|
| 17 | 26.6 | 11 | 10.5 | 7.44 (0.01) | 3.09 (1.34–7.13) |
|
| 9 | 14.1 | 3 | 2.9 | 5.97 (0.01) | 5.01 (1.41–17.8) |
|
| 6 | 9.4 | 28 | 26.7 | 6.36 (0.01) | 0.30 (0.12–0.76) |
|
| ||||||
| Women | ||||||
|
| 43 | 46.7 | 33 | 30.3 | 5.75 (0.02) | 2.02 (1.13–3.60) |
|
| 18 | 19.6 | 39 | 35.8 | 6.46 (0.01) | 0.44 (0.23–0.83) |
|
| 43 | 46.7 | 33 | 30.3 | 5.75 (0.02) | 2.02 (1.13–3.60) |
|
| 18 | 19.6 | 39 | 35.8 | 6.46 (0.01) | 0.44 (0.23–0.83) |
|
| 9 | 9.8 | 24 | 22.0 | 4.59 (0.03) | 0.40 (0.18–0.89) |
|
| 9 | 9.8 | 24 | 22.0 | 4.59 (0.03) | 0.40 (0.18–0.89) |
|
| 11 | 12.0 | 4 | 3.7 | 3.83 (0.05) | 3.31 (1.07–10.22) |
|
| 13 | 14.1 | 31 | 28.4 | 5.97 (0.01) | 0.41 (0.20–0.85) |
|
| 18 | 19.6 | 43 | 39.4 | 9.33 (0.002)* | 0.37 (0.20–0.71) |
1Means unadjusted P value. P value of 0.002 (P adj: adjusted for multiple tests) was set as statistically significant (*a statistically significant association).
Associations of genotype combinations with risk of nonallergic asthma (stratified by gender).
| Combinations of genotypes | Nonallergic asthma | Controls | Chi-square ( | OR (95% CI) | ||
|---|---|---|---|---|---|---|
|
| % |
| % | |||
| Men | ||||||
|
| 6 | 20.7 | 2 | 1.9 | 11.13 (0.001)* | 11.45 (2.49–52.66) |
|
| 4 | 13.8 | 3 | 2.9 | 3.50 (0.05) | 5.17 (1.20–22.31) |
|
| 5 | 17.2 | 4 | 3.8 | 4.58 (0.03) | 5.06 (1.37–18.99) |
|
| 6 | 20.7 | 5 | 4.8 | 5.68 (0.02) | 5.05 (1.49–17.14) |
|
| 5 | 17.2 | 4 | 3.8 | 4.58 (0.03) | 5.06 (1.35–18.99) |
|
| 11 | 37.9 | 15 | 14.3 | 8.12 (0.004) | 3.67 (1.47–9.28) |
|
| 8 | 27.6 | 3 | 2.9 | 15.31 (0.0001)* | 11.58 (3.07–43.72) |
|
| 4 | 13.8 | 1 | 1.0 | 7.16 (0.01) | 12.29 (1.84–82.03) |
|
| 5 | 17.2 | 1 | 1.0 | 10.55 (0.001)* | 15.64 (2.44–100.3) |
|
| 4 | 13.8 | 1 | 1.0 | 7.16 (0.01) | 12.29 (1.84–82.03) |
|
| 12 | 41.4 | 10 | 9.5 | 16.8 (0.00004)* | 6.71 (2.5–17.96) |
|
| 7 | 24.1 | 5 | 4.8 | 8.22 (0.004) | 6.09 (1.85–20.05) |
|
| ||||||
| Women | ||||||
|
| 2 | 7.4 | 0 | 0.0 | 3.88 (0.05) | 21.47 (1.00–461.1) |
|
| 6 | 22.2 | 56 | 51.4 | 6.29 (0.01) | 0.29 (0.11–0.74) |
|
| 2 | 7.4 | 0 | 0.0 | 3.88 (0.05) | 21.5 (1.00–461.2) |
|
| 1 | 3.7 | 24 | 22.0 | 3.69 (0.05) | 0.20 (0.04–1.09) |
|
| 7 | 25.9 | 4 | 3.7 | 11.58 (0.001)* | 8.58 (2.43–30.26) |
1Means unadjusted P value. P value adjusted for multiple tests (P adj) is less than 0.002 in men and 0.004 in women. *A statistically significant association.
Common biochemical abnormalities in redox homeostasis found in asthma and their possible relationship with genes for antioxidant defense enzymes which have been associated with risk of the disease in the present study.
| Biochemical abnormalities in asthmatics [references] | ADE gene related with the abnormality | Allergic asthma | Nonallergic asthma | ||
|---|---|---|---|---|---|
| Men | Women | Men | Women | ||
| Diminished capacity of glutathione peroxidases and catalase in detoxification of hydrogen peroxide [ |
| + + + | + + | + + | + + |
|
| + + | − | + + + | ||
|
| − | − | + + | − | |
|
| − | + | − | − | |
|
| + + + | − | + + | − | |
|
| |||||
| An enhanced production of ROS/hydrogen peroxide/superoxide anion radicals [ |
| − | + | − | − |
|
| − | − | + + + | − | |
|
| |||||
| Perturbations in glutathione (GSH) homeostasis [ |
| + + | − | + + + | − |
|
| + + | − | + + + | − | |
|
| |||||
| Increased EPHX1 activity, increased production of xenobiotics-generated epoxides, |
| + + | + + + | + + | + + + |
The number of pluses means a degree of the relationship between the gene and asthma risk. These measures reflect how many times a particular gene showed the link with asthma risk through the three methods used for evaluation of gene-gene interactions in the present study, namely, set association approach (SAA), multifactor dimensionality reduction (MDR) method, and post hoc association analysis of two-locus genotype combinations (AAGC): + + + means that the link was found thrice (i.e., using SAA, MDR, and AAGC methods); + + means that the link was found twice (i.e., using SAA or MDR and AAGC methods); + means that the link was found once by AAGC method. Associations are stratified by asthma type and gender.